Affiliation:
1. PSIT-Pranveer Singh Institute of Technology (Pharmacy), Bhautipratapur, Uttar Pradseh 209305, India
2. Phytochemistry Division, CSIR-Central Institute of Medicinal and Aromatic Plants, P.O.- CIMAP, Lucknow-226015, India
Abstract
Abstract:
Breast cancer is a widespread condition that kills more women from cancer-related
causes than any other type of cancer globally. Women who have estrogen-dependent, initial metastatic
breast cancer frequently receive treatment with surgery, radiation therapy, and chemotherapy.
They may also get more specialized treatments like tamoxifen or aromatase inhibitors (anastrozole
or letrozole). The World Health Organisation reported in 2012 that by 2030, breast cancer
will be more common worldwide. There are several phytochemicals, such as isoflavones, coumestans,
lignans, and prenylflavonoides. Isoflavones have been shown in studies to prevent the spread
of breast cancer and to trigger apoptosis. Targeting BCs in metastatic breast cancer may be made
possible by combining well-formulated phytochemicals in nanoparticles or other novel drug delivery
agents with currently accepted endocrine and/or conventional chemotherapies. Cell signaling,
regulation of cell cycles, oxidative stress action, and inflammation could be positively impacted
by phytoconstituents. They have the ability to alter non-coding RNAs, to prevent the proliferation
and regeneration of cancer cells. The availability of novel approaches helps in disease targeting,
safety, effectiveness and efficacy. The current literature helps to know the available drugs i.e. phytoconstituents
or novel drug delivery like nanoparticle, microsphere, micelles, liposomes and neosomes.
The literature has been taken from PubMed, Google Scholar, SciFinder, or other internet
sites.
Publisher
Bentham Science Publishers Ltd.